DYAI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DYAI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Dyadic International's Other Stockholders Equity for the quarter that ended in Sep. 2024 was $0.00 Mil.
Dyadic International's quarterly Other Stockholders Equity declined from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($-0.00 Mil) but then increased from Jun. 2024 ($-0.00 Mil) to Sep. 2024 ($0.00 Mil).
Dyadic International's annual Other Stockholders Equity declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($-0.00 Mil) but then increased from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil).
The historical data trend for Dyadic International's Other Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyadic International Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Other Stockholders Equity | Get a 7-Day Free Trial | - | - | - | - | - |
Dyadic International Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Other Stockholders Equity | Get a 7-Day Free Trial | - | - | - | - | - |
Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity
Thank you for viewing the detailed overview of Dyadic International's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Ronen Tchelet | officer: VP of Research and Bus. Dvlpmt | 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477 |
Mark A Emalfarb | director, 10 percent owner, officer: President, CEO & Chairman | C/O DYADIC INTERNATIONAL, INC., 140 INTRACOASTAL POINT DRIVE, SUITE 404, JUPITER FL 33477-5094 |
Joseph P Hazelton | officer: Chief Business Officer | 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER FL 33477 |
Francisco Trust Under Agreement Dated February 28, 1996 | 10 percent owner | C/O ROBERT S. LEVIN, ESQ., TRUSTEE, 180 NORTH LASALLE STREET, SUITE 3200, CHICAGO IL 60601 |
Patrick K. Lucy | director | C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121 |
Matthew S. Jones | officer: Managing Dir of BD & Licensing | 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477 |
Seth Herbst | director | 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477 |
Barry Buckland | director | C/O DYADIC INTERNATIONAL, INC., 140 INTERCOASTAL POINTE DR SUITE 404, JUPITER FL 33477 |
Ping Wang Rawson | officer: Chief Financial Officer | 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477 |
Michael P. Tarnok | director | KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Arindam Bose | director | 4452 BELTWAY DRIVE, ADDISON TX 75001 |
Jack Kaye | director | C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022 |
Tom Juda | 10 percent owner | 410 S LUCERNE BLVD, LOS ANGELES CA 90020 |
John Steven Emerson | 10 percent owner | 1522 ENSLEY AVENUE, LOS ANGELES CA 90024 |
Nancy Juda | 10 percent owner | 410 S LUCERNE BLVD, LOS ANGELES CA 90020 |
From GuruFocus
By GuruFocus Research • 03-29-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 05-30-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus News • 11-13-2024
By GuruFocus News • 11-12-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.